BioWednesday - How do Investors and Entrepreneurs Evaluate Intellectual Property?
17:30 - 20:00
BioWednesday Cambridge: How do Investors and Entrepreneurs Evaluate Intellectual Property?
We are delighted to invite you to attend our upcoming BioWednesday.
Statistics from CipherBio (illustrated below) exemplifies the Cambridge UK cluster and reveals the value of deals in Life Sciences in 2022 amounted to $421.1M. The vast majority in biotech, but a significant amount in Digital Health/AI too. Data also shows a strong proportion of deals from Seed and Series A fundraising.
An effective intellectual property (IP) strategy is key for helping biotech companies attract potential investors. Our panel will discuss how investors and entrepreneurs evaluate IP for company creation, fundraising and transactions. We will explore how companies can put themselves into the best possible position for successful IP due diligence, including in cases where patent protection may not always be possible. We hope that you can join us afterwards for networking and refreshments
Programme:
17.30 - Arrival and Registration
18.00 - Panel: How do Investors and Entrepreneurs Evaluate Intellectual Property?
19.00 - Networking and Light Refreshments
20.00 - Close
Panel
Edward Rainsford, Senior Associate, Appleyard Lees (Moderator)
Andrew Cook, Assistant General Counsel, IP, AstraZeneca
Iain Thomas, Head of Life Sciences, Cambridge Enterprise
Mike Romanos, Associate Dean for Enterprise, Faculty of Medicine, Imperial College
Prices
One Nucleus Members: free
Non-members: £50 + VAT
Academics: please contact alicia@onenucleus.com
Event Details
- Event: BioWednesday - How do Investors and Entrepreneurs Evaluate Intellectual Property?
- Date: Wed 01 Feb
- Time: 17:30 - 20:00